IRWD
Ironwood Pharmaceuticals, Inc. · Healthcare
Insiders sold $22.4M of Ironwood Pharmaceuticals, Inc. in the last 12 months and bought none
IRWD over the last year
IRWD after insider buys
3 months after each buy, from the first price a copier could get.
3 buys since 2021 with 3 months of prices.
Every filing
144 insider filings since 2016, newest first
Ronald Silver · PFO & PAO
Julie Mchugh · Director
Alexander J Denner · Director
Minardo John · General Counsel
Michael Shetzline · SVP, CMO, Head-Res, Drug
Thomas A Mccourt · CEO
Ronald Silver · Principal Accounting Officer
Ronald Silver · Principal Accounting Officer
Sravan Kumar Emany · SVP, COO and CFO
Minardo John · General Counsel
Julie Mchugh · Director
Catherine Moukheibir · Director
Thomas A Mccourt · CEO
Andrew Davis · SVP and Chief Business Officer
Michael Shetzline · CMO,SVP,Head-Res, Drug
Minardo John · General Counsel
Jon R Duane · Director
Sravan Kumar Emany · SVP and CFO
Minardo John · General Counsel
Michael Shetzline · CMO,SVP,Head-Res, Drug
Ronald Silver · Principal Accounting Officer
Andrew Davis · SVP and Chief Business Officer
Thomas A Mccourt · CEO
Marla L Kessler · Director
Andrew Davis · SVP and Chief Business Officer
Sravan Kumar Emany · SVP and CFO
Minardo John · General Counsel
Thomas A Mccourt · CEO
Michael Shetzline · CMO,SVP,Head-Res, Drug
Andrew Davis · SVP and Chief Business Officer
Thomas A Mccourt · CEO
Thomas A Mccourt · CEO
Thomas A Mccourt · CEO
Thomas A Mccourt · CEO
Ronald Silver · Principal Accounting Officer
Jason Rickard · SVP and COO
Thomas A Mccourt · CEO
Michael Shetzline · CMO,SVP,Head-Res, Drug
Minardo John · General Counsel
Andrew Davis · SVP and Chief Business Officer
Thomas A Mccourt · CEO
Jason Rickard · SVP and COO
Sravan Kumar Emany · SVP and CFO
Andrew Davis · SVP and Chief Business Officer
Thomas A Mccourt · CEO
Thomas A Mccourt · CEO
Minardo John · General Counsel
Mark G Currie · Director
Jason Rickard · SVP and COO
Thomas A Mccourt · CEO
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.